BioWorld

Aug. 14, 2002

View Archived Issues

Dendreon's Trp-p8 Gene Platform Garners $110M Genentech Deal

Dendreon Corp. could gain more than $110 million in a deal with Genentech Inc. to develop monoclonal antibodies, small molecules and other products from Dendreon's preclinical Trp-p8 gene platform. (BioWorld Today) Read More

Nobex Raises Two Year's Cash Through $35M Private Placement

Read More

GenVec's Flagship AntiCancer Drug, TNFerade, Performs Well In Both Preclinical, Clinical Trials

Read More

$37M Addition Brings Archemix Series A Financing To $51.75M

Read More

Other News To Note

Read More

CollaGenex Testing Periostat In Phase III Against Rosacea

Read More